Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Anti-IL-12 antibodies and compositions
US9676848B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9676848-B2 |
| Application number | US-201615198678-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 30, 2016 |
| Priority date | Aug 7, 2000 |
| Publication date | Jun 13, 2017 |
| Grant date | Jun 13, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
First claim
Opening claim text (preview).
What is claimed is: 1. A pen-injector containing a liquid pharmaceutical formulation comprising an effective amount of an isolated anti-IL-12 antibody having a heavy chain variable region and a light chain variable region, said heavy chain variable region comprising: a heavy chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:1, a heavy chain complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO:2, a heavy chain complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO:3, said light chain variable region comprising: a light chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO:5, and a light chain complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO:6. 2. The pen-injector according to claim 1 , wherein the liquid pharmaceutical formulation comprises histidine buffer, polysorbate 80 and sucrose. 3. The pen-injector according to claim 1 , wherein the pH is about 6.0. 4. The pen-injector according to claim 1 , wherein said effective amount is 45 mg of antibody. 5. The pen-injector according to claim 1 , wherein said effective amount is 90 mg of antibody. 6. A pen-injector containing a liquid pharmaceutical formulation comprising an effective amount of an isolated anti-IL-12 antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8. 7. The pen-injector according to claim 6 , wherein the liquid pharmaceutical formulation comprises histidine buffer, polysorbate 80 and sucrose. 8. The pen-injector according to claim 6 , wherein the pH is about 6.0. 9. The pen-injector according to claim 6 , wherein said effective amount is 45 mg of antibody. 10. The pen-injector according to claim 6 , wherein said effective amount is 90 mg of antibody.
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunostimulants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9676848B2 cover?
- Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
- Who is the assignee on this patent?
- Giles-Komar Jill, Knight David M, Peritt David, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/244. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).